
News|Articles|March 1, 2011
FDA Pipeline Preview, March 2011 (Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib)
Recent FDA action (through, February 2011) related to Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib.
Advertisement
Complete response
Fast-track designation
Priority review
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patients may not see savings from new Medicare drug programs
2
Sanofi acquires Dynavax for $2.2 billion to bolster vaccine portfolio
3
Why Timing, Access and Interpretation Matter in Oncology Biomarker Testing
4
AHIP lays blame for rising healthcare costs on hospitals, private equity
5




















































